drugset / Trial / NCT00412776

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

NCT00412776 ↗

Phase 2/3 Terminated 165 enrolled Sesen Bio, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.

Timeline

Start
2005-12
Primary completion
2008-04
Completion
2008-04

Outcome

Outcome not reported

Stopped: “Corporate reasons unrelated to safety and efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject Proxinium Protein / enzyme biologic 700 ug Other